<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024631</url>
  </required_header>
  <id_info>
    <org_study_id>831865</org_study_id>
    <nct_id>NCT04024631</nct_id>
  </id_info>
  <brief_title>Phenotyping Genetic Risk for Type 2 Diabetes</brief_title>
  <official_title>Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that non-diabetic individuals with a high genetic risk score
      for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those
      with a low genetic risk score for type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team will recruit individuals based on genetic risk score for type 2 diabetes from
      the biobank populations who have agreed to be recontacted for future research. Each
      participant will undergo a frequently sampled four-hour oral glucose tolerance test and whole
      body DXA scan (dual-energy X-ray absorptiometry) in addition to baseline laboratory and
      history assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>cross sectional</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Data analyses (including by outcomes assessors and investigators) will be de-identified, and individuals performing laboratory analyses and DXA interpretation will be blinded to polygenic risk score for type 2 diabetes. Participants and nursing staff will not be informed of polygenic risk score at the time of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose response to an oral glucose load</measure>
    <time_frame>samples will be collected over four hours and these results will be used to calculate area under the curve</time_frame>
    <description>Glucose area under the curve after the 75g glucose beverage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visceral adiposity index</measure>
    <time_frame>DXA scan will be obtained on the same day as the oral glucose test and will be completed in less than 30 minutes</time_frame>
    <description>DXA whole body scan visceral adiposity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>calculated from baseline fasting insulin and glucose levels</time_frame>
    <description>Insulin resistance estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disposition index</measure>
    <time_frame>samples will be collected over four hours after the 75g glucose beverage and these results will be used for mixed modeling</time_frame>
    <description>product of insulin sensitivity and amount of insulin released; calculated using mixed modeling techniques</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Genetics</condition>
  <arm_group>
    <arm_group_label>Phenotyping</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.
They will also undergo a whole body DXA (intervention) during the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>75g glucose beverage (Glucola, Trutol, or similar brand)</intervention_name>
    <description>Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.</description>
    <arm_group_label>Phenotyping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DXA, whole body</intervention_name>
    <description>Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.</description>
    <arm_group_label>Phenotyping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10-70 years

          -  Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and
             agreed to be recontacted for future research.

          -  Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile
             or higher

        Exclusion Criteria:

          -  prior diagnosis of type 1, type 2, or secondary diabetes

          -  use of medications that would impact glucose and insulin response such as steroids,
             metformin or other anti-diabetic medication

          -  acute illness that may impact insulin and glucose dynamics

          -  pregnancy

          -  hypothalamic obesity or related genetic disorder of metabolism

          -  recent systemic chemotherapy use

          -  gastrointestinal impairment or surgery that may impact absorption

          -  anemia

          -  major organ system illness or any underlying condition requiring regular medication or
             treatment that could make implementation of the protocol or interpretation of the
             study results difficult

          -  inability to comply with study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica R Wilson, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorraine Levitt Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica R Wilson, MD, MS</last_name>
    <phone>215 898-3389</phone>
    <email>jessica.wilson3@uphs.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Oyerinde</last_name>
    <email>esther.oyerinde@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica R Wilson, MD, MS</last_name>
      <phone>215-898-3389</phone>
      <email>jessica.wilson3@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Esther Oyerinde</last_name>
      <email>esther.oyerinde@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica R Wilson, MD, MS</last_name>
      <phone>215-898-3389</phone>
      <email>jessica.wilson3@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Esther Oyerinde</last_name>
      <email>esther.oyerinde@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 13, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Jessica R.Wilson, MD, MS</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>polygenic risk for type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

